Source: Cancer Network, June 2025
Practice Setting Considerations and Treatment Selection
Key Discussion Points:
- Immunotherapy management in community vs academic settings
- Logistical factors influencing treatment selection
- Community oncologist experience with immunotherapy regimens
Key Points for Physicians:
- Community oncologists have developed increasing expertise in managing immune-related adverse events with combination regimens
- Nivolumab/relatlimab adoption in community settings has been facilitated by its less intensive administration schedule (30-minute infusion every 4 weeks) and lower toxicity profile